Several other equities analysts also recently weighed in on the stock. Roth Capital lifted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research note on Tuesday, November 19th. Piper Jaffray Companies reissued a buy rating and set a $104.00 target price on shares of Crispr Therapeutics in a report on Tuesday, November 26th. BidaskClub raised Crispr Therapeutics from a buy rating to a strong-buy rating in a report on Saturday, November 30th. Finally, Oppenheimer lifted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research report on Monday, November 25th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Crispr Therapeutics currently has a consensus rating of Buy and a consensus target price of $69.54.
Shares of CRSP opened at $72.37 on Friday. The business has a 50-day moving average of $54.81 and a 200 day moving average of $47.38. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The firm has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth about $4,366,000. Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the third quarter worth approximately $21,167,000. Granahan Investment Management Inc. MA lifted its stake in shares of Crispr Therapeutics by 8.3% in the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock worth $1,418,000 after buying an additional 2,655 shares in the last quarter. Barclays PLC grew its holdings in shares of Crispr Therapeutics by 42.7% during the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock valued at $568,000 after buying an additional 4,151 shares during the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of Crispr Therapeutics by 18.0% during the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock valued at $400,000 after buying an additional 1,491 shares during the last quarter. 49.82% of the stock is currently owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What are earnings reports?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.